The global influenza drug market size is calculated at USD 1.12 billion in 2025 and is forecasted to reach around USD 1.38 billion by 2034, accelerating at a CAGR of 2.39% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Influenza Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Influenza Drug Market Revenue and Volume Forecast, by Type
8.1.1. Antiviral Medications
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Vaccines
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Immunomodulators
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Symptomatic Treatments
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Combination Therapies
8.1.5.1. Market Revenue and Volume Forecast
9.1. Influenza Drug Market Revenue and Volume Forecast, by Mechanism of Action
9.1.1. Neuraminidase Inhibitors
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Cap-dependent Endonuclease Inhibitors
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Fusion Inhibitors
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. M2 Ion Channel Inhibitors
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Host Cell Protease Inhibitors
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Immunomodulatory Agents
9.1.6.1. Market Revenue and Volume Forecast
9.1.7. RNA Polymerase Inhibitors
9.1.7.1. Market Revenue and Volume Forecast
9.1.8. Hemagglutinin Stem Binders
9.1.8.1. Market Revenue and Volume Forecast
9.1.9. Cytokine Inhibitors
9.1.9.1. Market Revenue and Volume Forecast
9.1.10. Host Factor Targeting
9.1.10.1. Market Revenue and Volume Forecast
10.1. Influenza Drug Market Revenue and Volume Forecast, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intranasal
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Intravenous
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Intramuscular
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Subcutaneous
10.1.5.1. Market Revenue and Volume Forecast
11.1. Influenza Drug Market Revenue and Volume Forecast, by End-user
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Vaccination Centers
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Research Institutions
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Government Health Agencies
11.1.5.1. Market Revenue and Volume Forecast
11.1.6. Long-term Care Facilities
11.1.6.1. Market Revenue and Volume Forecast
11.1.7. Community Health Centers
11.1.7.1. Market Revenue and Volume Forecast
11.1.8. Corporate Health Programs
11.1.8.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Type
12.1.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.1.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.4. Market Revenue and Volume Forecast, by End-user
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Type
12.1.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.4. Market Revenue and Volume Forecast, by End-user
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Type
12.1.6.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.4. Market Revenue and Volume Forecast, by End-user
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Type
12.2.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.2.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.4. Market Revenue and Volume Forecast, by End-user
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Type
12.2.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.4. Market Revenue and Volume Forecast, by End-user
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Type
12.2.6.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.4. Market Revenue and Volume Forecast, by End-user
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Type
12.2.7.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.4. Market Revenue and Volume Forecast, by End-user
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Type
12.2.8.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.4. Market Revenue and Volume Forecast, by End-user
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Type
12.3.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.3.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.4. Market Revenue and Volume Forecast, by End-user
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Type
12.3.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.4. Market Revenue and Volume Forecast, by End-user
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Type
12.3.6.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.4. Market Revenue and Volume Forecast, by End-user
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Type
12.3.7.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.4. Market Revenue and Volume Forecast, by End-user
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Type
12.3.8.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.4. Market Revenue and Volume Forecast, by End-user
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Type
12.4.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.4.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.4. Market Revenue and Volume Forecast, by End-user
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Type
12.4.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.4. Market Revenue and Volume Forecast, by End-user
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Type
12.4.6.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.4. Market Revenue and Volume Forecast, by End-user
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Type
12.4.7.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.4. Market Revenue and Volume Forecast, by End-user
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Type
12.4.8.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.4. Market Revenue and Volume Forecast, by End-user
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Type
12.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.4. Market Revenue and Volume Forecast, by End-user
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Type
12.5.5.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.4. Market Revenue and Volume Forecast, by End-user
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Type
12.5.6.2. Market Revenue and Volume Forecast, by Mechanism of Action
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.4. Market Revenue and Volume Forecast, by End-user
13.1. Daiichi Sankyo Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Natco Pharma
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Teva Pharmaceutical
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sandoz International
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Sun Pharmaceutical Industries
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Mylan
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample